Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.65 |
| ▸ | STING1 | Q86WV6 | 13/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.63 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | PRKACG | P22612 | 1/20 | 0.56 |
| ▸ | PRKACB | P22694 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150583 | 0.88 | RXFP1 (0.51) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL1133093 | 0.85 | KMT2A (0.76) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL10239446 | 0.85 | KMT2A (0.76) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL15906324 | 0.85 | KMT2A (0.76) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL1106673 | 0.85 | KMT2A (0.76) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL17826615 | 0.84 | KMT2A (0.69) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL29515507 | 0.80 | KMT2A (1.00) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL10098850 | 0.80 | KMT2A (1.00) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL4159569 | 0.80 | KMT2A (1.00) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 | |
| SCHEMBL1106664 | 0.80 | KMT2A (1.00) | RXFP1KMT2AMEN1ALDH1A1RAPGEF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9365605-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2012088155-A1 | CYCLIC NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002037-A1 | CYCLIC NUCLEOTIDE ANALOGS | NT5C2, NTPCR, PNP | RXFP1 3386/4885KMT2A 3789/4885MEN1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.